102 related articles for article (PubMed ID: 16112085)
21. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
[TBL] [Abstract][Full Text] [Related]
22. Variations in the APP gene promoter region and risk of Alzheimer disease.
Guyant-Maréchal L; Rovelet-Lecrux A; Goumidi L; Cousin E; Hannequin D; Raux G; Penet C; Ricard S; Macé S; Amouyel P; Deleuze JF; Frebourg T; Brice A; Lambert JC; Campion D
Neurology; 2007 Feb; 68(9):684-7. PubMed ID: 17325276
[TBL] [Abstract][Full Text] [Related]
23. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
24. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer.
Santos AM; Sousa H; Pinto D; Portela C; Pereira D; Catarino R; Duarte I; Lopes C; Medeiros R
Eur J Cancer; 2006 May; 42(7):958-63. PubMed ID: 16542834
[TBL] [Abstract][Full Text] [Related]
25. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):854-9. PubMed ID: 16467099
[TBL] [Abstract][Full Text] [Related]
26. Endostatin gene variation and protein levels in breast cancer susceptibility and severity.
Balasubramanian SP; Cross SS; Globe J; Cox A; Brown NJ; Reed MW
BMC Cancer; 2007 Jun; 7():107. PubMed ID: 17587451
[TBL] [Abstract][Full Text] [Related]
27. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
[TBL] [Abstract][Full Text] [Related]
28. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
[TBL] [Abstract][Full Text] [Related]
29. Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene.
Schürks M; Kurth T; Geissler I; Tessmann G; Diener HC; Rosskopf D
Neurology; 2006 Jun; 66(12):1917-9. PubMed ID: 16554494
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
[TBL] [Abstract][Full Text] [Related]
31. Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer.
Leite DB; Junqueira MG; de Carvalho CV; Massad-Costa AM; Gonçalves WJ; Nicolau SM; Lopes LA; Baracat EC; da Silva ID
Steroids; 2008 Jul; 73(6):676-80. PubMed ID: 18384825
[TBL] [Abstract][Full Text] [Related]
32. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
Kamikozuru H; Kuramochi H; Hayashi K; Nakajima G; Yamamoto M
Int J Oncol; 2008 May; 32(5):1091-6. PubMed ID: 18425336
[TBL] [Abstract][Full Text] [Related]
33. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Potter JD; Ulrich CM
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):502-8. PubMed ID: 16537708
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
35. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
[TBL] [Abstract][Full Text] [Related]
36. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
37. Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma.
Lu Z; Wang Y; Zhang Q; Zhang X; Wang S; Xie H; Li Y; Jiao B; Zhang J
Brain Res; 2006 Nov; 1118(1):6-12. PubMed ID: 16956593
[TBL] [Abstract][Full Text] [Related]
38. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
39. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
40. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Drzezga A; Grimmer T; Riemenschneider M; Lautenschlager N; Siebner H; Alexopoulus P; Minoshima S; Schwaiger M; Kurz A
J Nucl Med; 2005 Oct; 46(10):1625-32. PubMed ID: 16204712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
